Roivant Sciences to Take Public via Montes Archimedes Acquisition Corp (MAAC) Business Combination

Talawar Therapeutics to Go Public via Business Combination with JATT II Acquisition Corp

June 29, 2026

Biotechnology

Talawar Therapeutics entered into a definitive business combination agreement with JATT II Acquisition Corp to create a publicly listed biotechnology company focused on developing bispecific antibodies for immunology and inflammatory diseases. The transaction is expected to close in the second half of 2026 and includes an oversubscribed $225 million PIPE alongside $60 million held in JATT II’s trust account (assuming no redemptions).

ARCHIMED to Acquire Esperion Therapeutics in Up to $1.1B Deal

May 1, 2026

Healthcare Services

ARCHIMED, via a fund-managed affiliate, signed a definitive agreement to acquire Esperion Therapeutics for $3.16 per share in cash, valuing the transaction at up to approximately $1.1 billion including commercial milestone payments. Esperion shareholders will also receive a contingent value right (CVR) for up to $100 million in additional milestones tied to future U.S. net sales of bempedoic acid- and bumetanide-containing products.

Avant Technologies Proposes Acquisition of Ainnova Tech to Consolidate Vision AI JV

May 13, 2025

Healthcare Services

Avant Technologies has entered formal negotiations to acquire its joint-venture partner Ainnova Tech (operating through Ai-nova Acquisition Corp.), aiming to merge the businesses ahead of an FDA pre-submission meeting. The deal is intended to streamline regulatory coordination, speed clinical development and support U.S. market entry for the Vision AI clinical screening platform currently piloted across Latin America.

Roche Buys Telavant Holdings (Roivant/Pfizer) for $7.1B+

October 26, 2023

Healthcare Services

Roche entered into a definitive agreement to acquire Telavant Holdings, a company jointly owned by Roivant and Pfizer, for an upfront purchase price of $7.1 billion plus a near-term $150 million milestone payment. The deal gives Roche full rights to further develop, manufacture, and commercialize Telavant’s TL1A-directed antibody RVT-3101 in the US and Japan, with Pfizer retaining commercialization rights outside those territories.

ARCHIMED Acquires Majority Stake in Cube (Cube Biotech)

November 3, 2021

Biotechnology

Transatlantic healthcare private equity firm ARCHIMED has purchased a majority stake in Monheim, Germany-based Cube (Cube Biotech), a specialist provider of high-purity, stable membrane proteins for drug discovery. ARCHIMED will support Cube's US market expansion and broaden its product and service offering organically and via acquisitions while Cube's founding management remain significant shareholders and continue to lead the business.

Merck to Acquire Acceleron Pharma Inc for $11.5B

September 30, 2021

Biotechnology

Merck (through a subsidiary) entered into a definitive agreement to acquire Acceleron Pharma Inc for $180 per share in cash, for an approximate total equity value of $11.5 billion. The transaction will be completed via a tender offer followed by a merger, and is expected to close in the fourth quarter of 2021, subject to conditions including regulatory approvals and tender of at least a majority of outstanding shares.